Survival Analyses of Clene Expanded Access Programs in ALS
Feb 22, 2024
Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2024 Clene Nanomedicine, Inc. - All rights reserved | PRIVACY POLICY | TERMS OF USE